After a short stint at Intercept, Rachel McMinn makes the leap from biotech analyst to biotech CEO
Over a 13-year career as a biotech analyst at Piper Jaffray, Cowen and Bank of America Merrill Lynch, Rachel McMinn learned a lot about the industry. Enough to think that maybe she should be the one running the company rather than just asking questions — and discussing options — related to its performance.
“Over time I felt I was giving a lot of companies free advice,” McMinn says. “I felt that maybe I could do it.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
